Here are three things to know:
1. For the study, researchers will conduct a randomized controlled trial comparing an antiviral drug and three different antibody treatments to each other with no placebo.
2. Due to the escalating violence in the Congo, the researchers conducting the trial are expected to face complications.
“I don’t think the world quite appreciates the challenge of the environment in which this is happening,” said Jeremy Farrar, MD, head of the Wellcome Trust and co-chair of a group that has been working under the auspices of the World Health Organization to draft the trial protocol. “People are being shot at, and it’s not just the occasional bit of gunfire.There’s mortars, there’s kidnappings — it is an intensely fragile environment with a lot of conflict that’s been going on for years.”
3. The trial is set to begin in the middle of November. As of Nov. 9, there have been 139 patients who received one of the four vaccines. The World Health Organization confirmed 329 probable Ebola causes and 205 deaths.
More articles on clinical leadership and infection control:
Many hospital linens contaminated with mold, study finds
Most destructive wildfire in California history may have long-lasting health repercussions
Wildfire smoke reaches toxic ’emergency’ levels in Sacramento
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.